GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Cyclically Adjusted PB Ratio

INVO Bioscience (INVO Bioscience) Cyclically Adjusted PB Ratio : (As of Jun. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


INVO Bioscience Cyclically Adjusted PB Ratio Historical Data

The historical data trend for INVO Bioscience's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Bioscience Cyclically Adjusted PB Ratio Chart

INVO Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

INVO Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of INVO Bioscience's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, INVO Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Bioscience's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, INVO Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where INVO Bioscience's Cyclically Adjusted PB Ratio falls into.



INVO Bioscience Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

INVO Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, INVO Bioscience's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.479/131.7762*131.7762
=-2.479

Current CPI (Mar. 2024) = 131.7762.

INVO Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201212 -25.946 96.871 -35.295
201312 -29.346 98.326 -39.329
201412 -33.531 99.070 -44.601
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 -17.540 99.792 -23.162
201603 -18.385 100.470 -24.114
201606 -18.800 101.688 -24.363
201609 -19.761 101.861 -25.565
201612 -21.021 101.863 -27.194
201703 -21.381 102.862 -27.391
201706 -21.761 103.349 -27.747
201709 -22.044 104.136 -27.895
201712 -22.478 104.011 -28.478
201803 -21.814 105.290 -27.302
201806 -17.938 106.317 -22.234
201809 -19.219 106.507 -23.779
201812 -11.299 105.998 -14.047
201903 -12.839 107.251 -15.775
201906 -12.998 108.070 -15.849
201909 -15.470 108.329 -18.818
201912 -15.206 108.420 -18.482
202003 -17.990 108.902 -21.769
202006 -14.574 108.767 -17.657
202009 -15.753 109.815 -18.903
202012 11.916 109.897 14.288
202103 10.740 111.754 12.664
202106 8.333 114.631 9.579
202109 4.960 115.734 5.648
202112 12.257 117.630 13.731
202203 9.248 121.301 10.047
202206 5.533 125.017 5.832
202209 2.116 125.227 2.227
202212 -1.607 125.222 -1.691
202303 0.126 127.348 0.130
202306 -2.062 128.729 -2.111
202309 0.151 129.860 0.153
202312 -2.049 129.419 -2.086
202403 -2.479 131.776 -2.479

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


INVO Bioscience  (NAS:INVO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


INVO Bioscience Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Bioscience (INVO Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880